INNOVATE’s Portfolio Company, R2, has Explosive Growth and Global Reach with Glacial® Skin Continuing to Redefine Aesthetic Innovation
INNOVATE Corp. (NYSE:VATE) announced exceptional Q2 2025 performance for its subsidiary R2 Technologies, developer of Glacial® Skin technology. R2 achieved an 88% year-over-year revenue growth in Q2 2025, with global system sales surging 125% compared to Q2 2024.
Key highlights include a 768% growth in demand outside North America for H1 2025, 115% increase in patient treatments, and 28% rise in monthly provider utilization. The company's digital presence showed remarkable growth with 823% above-industry-benchmark social media engagement, 52% quarter-over-quarter growth in social mentions, and 141% increase in website traffic.
The global non-invasive aesthetic market is projected to grow from $83.13 billion in 2025 to $238 billion by 2034, with a 12.4% CAGR.
INNOVATE Corp. (NYSE:VATE) ha comunicato risultati straordinari nel secondo trimestre 2025 per la sua controllata R2 Technologies, sviluppatrice della tecnologia Glacial®. R2 ha registrato una crescita dei ricavi del 88% su base annua nel Q2 2025, con le vendite di sistemi a livello mondiale in aumento del 125% rispetto al Q2 2024.
Tra i punti salienti: una domanda al di fuori del Nord America cresciuta del 768% nel primo semestre 2025, un incremento del 115% nei trattamenti erogati ai pazienti e un aumento del 28% nell'utilizzo mensile da parte dei fornitori. La presenza digitale dell'azienda è aumentata sensibilmente con un coinvolgimento sui social media superiore del 823% rispetto alla media del settore, un aumento delle menzioni social del 52% trimestre su trimestre e un incremento del 141% del traffico web.
Si prevede che il mercato estetico globale non invasivo passerà da $83,13 miliardi nel 2025 a $238 miliardi entro il 2034, con un tasso di crescita annuo composto (CAGR) del 12,4%.
INNOVATE Corp. (NYSE:VATE) informó un desempeño excepcional en el 2T 2025 de su filial R2 Technologies, desarrolladora de la tecnología Glacial®. R2 alcanzó un 88% de crecimiento interanual en ingresos en el 2T 2025, con ventas globales de sistemas que se dispararon un 125% respecto al 2T 2024.
Entre los puntos clave figura un crecimiento del 768% en la demanda fuera de Norteamérica durante el 1S 2025, un aumento del 115% en tratamientos a pacientes y una subida del 28% en la utilización mensual por parte de los proveedores. La presencia digital de la compañía mostró un crecimiento notable con un compromiso en redes sociales un 823% por encima del referente sectorial, un 52% de crecimiento trimestre a trimestre en menciones sociales y un aumento del 141% en el tráfico web.
Se proyecta que el mercado estético no invasivo global crecerá de $83,13 mil millones en 2025 a $238 mil millones en 2034, con un CAGR del 12,4%.
INNOVATE Corp. (NYSE:VATE)는 자회사 R2 Technologies(Glacial® 스킨 기술 개발사)의 2025년 2분기 우수한 실적을 발표했습니다. R2는 2025년 2분기 매출이 전년 동기 대비 88% 증가했으며, 전 세계 시스템 판매는 2024년 2분기 대비 125% 급증했습니다.
주요 내용으로는 2025년 상반기 북미 외 지역 수요가 768% 증가, 환자 시술 수가 115% 늘어났고 월별 제공자 이용률이 28% 상승한 점이 포함됩니다. 디지털 채널도 크게 성장해 소셜 미디어 참여도가 업계 기준보다 823% 높게 나타났고, 소셜 언급은 분기 대비 52% 증가, 웹사이트 트래픽은 141% 상승했습니다.
비수술 미용 시장은 2025년 $83.13억에서 2034년 $238억으로, 연평균 성장률(CAGR) 12.4%로 확대될 것으로 예상됩니다.
INNOVATE Corp. (NYSE:VATE) a annoncé des performances exceptionnelles au 2e trimestre 2025 pour sa filiale R2 Technologies, développeur de la technologie Glacial®. R2 a réalisé une croissance des revenus de 88% en glissement annuel au T2 2025, avec des ventes mondiales de systèmes en hausse de 125% par rapport au T2 2024.
Parmi les faits marquants : une augmentation de la demande hors Amérique du Nord de 768% au 1er semestre 2025, une hausse de 115% des traitements aux patients et une augmentation de 28% de l'utilisation mensuelle par les prestataires. La présence digitale de l'entreprise a connu une forte croissance, avec un engagement sur les réseaux sociaux supérieur de 823% au benchmark sectoriel, une augmentation des mentions sociales de 52% d'un trimestre à l'autre et une progression de 141% du trafic web.
Le marché mondial de l'esthétique non invasive devrait passer de 83,13 milliards $ en 2025 à 238 milliards $ d'ici 2034, avec un CAGR de 12,4%.
INNOVATE Corp. (NYSE:VATE) meldete herausragende Ergebnisse für Q2 2025 seiner Tochtergesellschaft R2 Technologies, Entwickler der Glacial® Skin-Technologie. R2 verzeichnete im Q2 2025 ein 88%iges Umsatzwachstum gegenüber dem Vorjahr, wobei die weltweiten Systemverkäufe im Vergleich zum Q2 2024 um 125% zulegten.
Zu den Highlights zählen eine 768%ige Steigerung der Nachfrage außerhalb Nordamerikas im H1 2025, ein 115%iger Anstieg bei Patientenbehandlungen und eine 28%ige Erhöhung der monatlichen Anbieter-Auslastung. Die digitale Präsenz des Unternehmens wuchs deutlich: Social-Media-Engagement lag 823% über dem Branchenbenchmark, soziale Erwähnungen stiegen quartalsübergreifend um 52% und der Website-Traffic nahm um 141% zu.
Der globale Markt für nicht-invasive Ästhetik soll von $83,13 Milliarden im Jahr 2025 auf $238 Milliarden bis 2034 wachsen, mit einer 12,4%igen CAGR.
- None.
- None.
Insights
R2's Glacial Skin shows exceptional quarterly growth with 88% revenue increase and 768% international expansion, positioning INNOVATE for strong returns in the booming aesthetics market.
The performance metrics for R2 Technologies paint a compelling picture of accelerating market penetration in the high-growth aesthetics sector. The 88% year-over-year revenue increase in Q2 2025 demonstrates remarkable commercial traction, but even more impressive is the 125% surge in global system sales. This suggests the company is successfully executing its international expansion strategy, particularly evidenced by the 768% growth outside North America for the first half of 2025.
The operational metrics are equally impressive. The 115% increase in patient treatments coupled with a 28% rise in monthly utilization per provider indicates strong product-market fit and growing provider adoption. These metrics matter because they represent the two critical components of medical device economics: increasing installed base and higher utilization rates per installation.
From a market positioning perspective, Glacial Skin has cleverly positioned itself at the intersection of two powerful consumer trends: non-invasive treatments and wellness-focused skincare. The global non-invasive aesthetic market projection of
R2's digital engagement metrics, including
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced that R2 Technologies, Inc. (“R2”), the innovators behind the breakthrough Glacial® Skin technology, and an operating subsidiary of INNOVATE, achieved a second-quarter 2025 revenue increase of
R2’s global system sales surged
Glacial Skin’s Clinical & Business Impact
Glacial Skin delivers controlled cooling to reduce inflammation, brighten skin, and correct pigment, all with zero downtime. In Q2 2025, patient treatments increased
Brand Awareness & Digital Engagement
Glacial Skin, a pioneering wellness brand, is redefining the aesthetics landscape with a surge in brand awareness and digital engagement that is capturing the attention of both providers and consumers. This surge in digital engagement is translating into increased provider inquiries and accelerated system adoption. Glacial Skin’s social media engagement is outperforming industry benchmarks by an impressive
This summer, R2 unveiled its new tagline Restore, Refresh, Rebalance, a powerful reflection of the core wellness benefits delivered by each Glacial Skin treatment, from reducing inflammation to promoting radiant, balanced skin. With momentum continuing to build, R2 believes that Glacial Skin is poised to lead the next wave of growth in the aesthetic wellness technology sector.
“Our Q2 results are a testament to the global appeal of Glacial Skin and the exceptional outcomes it delivers for patients and providers alike,” said Tim Holt, CEO of R2 Technologies. “We’re not only redefining what’s possible in skin health but also delivering a compelling return on investment for our partners worldwide.”
Glacial Skin is positioned to lead the growing demand for non-invasive, inflammation-targeted treatments. As consumers increasingly seek effective solutions with minimal downtime, the global non-invasive aesthetic market is projected to grow from USD 83.13 billion in 2025 to USD 238 billion by 2034, reflecting a
“As highlighted in NewBeauty’s Summer 2025 Supplement, today’s patients are making wellness-driven decisions; they want visible results with no downtime,” said Tim Holt, CEO of R2 Technologies. “Glacial Skin is uniquely positioned to meet that demand, combining clinical efficacy with a wellness-first experience that resonates globally.”
About INNOVATE
INNOVATE is a portfolio of best-in-class assets in three key areas of the new economy – Infrastructure, Life Sciences and Spectrum. Dedicated to stakeholder capitalism, INNOVATE employs approximately 3,100 people across its subsidiaries. For more information, please visit: www.INNOVATECorp.com.
About R2 Technologies, Inc.
Headquartered in Silicon Valley is the world leader in CryoAesthetics® medical devices. Founded in 2014 by Pansend Life Sciences LLC, Blossom Innovations LLC, and Massachusetts General Hospital, R2 Technologies has pioneered the development of Glacial® Skin platforms for precision contact cooling of the skin, which has been shown to reduce inflammation and brighten the skin.
R2 Technologies' product lineup includes Glacial® Rx, Glacial® fx, and Glacial® Spa, with an exciting pipeline of future innovations in development. The company's strategic partnership with Huadong Medicine Co., Ltd. has further accelerated its growth and market presence.
To learn more about R2 Technologies, treatment offerings, and providers, visit glacialskin.com and follow the company on LinkedIn and Instagram.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements generally relate to future events, including, but not limited to, statements regarding the continued growth of sales of R2’s Glacial systems, and the anticipated growth in the non-invasive aesthetic market and skin rejuvenation segment. You are cautioned that such statements are not guarantees of future performance and that INNOVATE’s actual results may differ materially from those set forth in the forward-looking statements. All of these forward-looking statements are subject to risks and uncertainties that may change at any time. Factors that could cause INNOVATE’s actual expectations to differ materially from these forward-looking statements include customer demand, patient satisfaction with procedures, and the impact of general economic conditions, our ability to successfully implement our growth strategy and grow our business effectively or efficiently, R2’s reliance on third parties for its sales, marketing, manufacturing and/or distribution and the other factors under the heading “Risk Factors” set forth in INNOVATE’s Annual Report on Form 10-K, as supplemented by INNOVATE’s quarterly reports on Form 10-Q. Such filings are available on our website or at www.sec.gov. You should not place undue reliance on these forward-looking statements, which are made only as of the date of this press release. INNOVATE undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws.
Investor Contact
Solebury Strategic Communications
Anthony Rozmus
ir@innovatecorp.com
(212) 235-2691
1 Towards Healthcare, 2025
2 Market Research Future, 2025
FAQ
What was R2 Technologies' revenue growth in Q2 2025 for INNOVATE Corp (NYSE:VATE)?
How has Glacial Skin's international market performance evolved in 2025?
What are the key performance metrics for Glacial Skin treatments in Q2 2025?
What is the projected market size for non-invasive aesthetics by 2034?
How has Glacial Skin's digital engagement performed in 2025?
